Cite
HARVARD Citation
Faehling, M. et al. (2020). Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung cancer. pp. 114-122. [Online].